Biotech, Diagnostics, cancer Luke Timmerman wrote: Sequenom, the San Diego-based developer of a non-invasive prenatal test for Down Syndrome, said today it has acquired Ann Arbor, MI-based SensiGen for $8.7 million, plus potential milestones. The deal gives Sequenom (NASDAQ: SQNM) molecular diagnost...

deals, Life Sciences, Diagnostics Ryan McBride wrote: San Diego diagnostics firm Sequenom (NASDAQ:SQNM) says it plans to acquire all shares of cancer test maker Exact Sciences’ common stock (NASDAQ:EXAS), despite a rejection from Exact’s board of directors to Sequenom’s recent buyo...

Biotech, acquisitions, Diagnostics Luke Timmerman wrote: San Diego-based Sequenom is flexing some of its newfound muscle, by making a takeover bid for Marlborough, MA-based Exact Sciences while it is on the ropes. Sequenom (NASDAQ: SQNM) said today after markets closed it is offering $1.50 worth of ...

Biotech, Diagnostics, Cystic Fibrosis Luke Timmerman wrote: Sequenom has its sights on developing more than just the first non-invasive prenatal test for Down syndrome. Today, scientists affiliated with the San Diego-based biotech company are reporting how their methods of analyzing genes in a sampl...